source
- #ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts sayCHICAGO — Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready to be used as a regular screening tool, experts not involved ...Endpoints · 2mo ago↗ source
- Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and moreWelcome back to Endpoints Weekly! We’ve got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author Max Gelman. If you haven’t already, check out Ma…Endpoints · 2mo ago↗ source
- Next FDA user fee deal is under review at the White HouseThe White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sour…